The latest price target for Orchestra BioMed Hldgs (NASDAQ:OBIO) was reported by B. Riley Securities on May 19, 2026. The analyst firm set a price target for $10.00 expecting OBIO to rise to within 12 months (a possible 157.73% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ:OBIO) was provided by B. Riley Securities, and Orchestra BioMed Hldgs maintained their buy rating.

There is no last upgrade for Orchestra BioMed Hldgs

The last downgrade for Orchestra BioMed Holdings Inc happened on August 20, 2025 when BTIG changed their price target from N/A to N/A for Orchestra BioMed Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on May 19, 2026 so you should expect the next rating to be made available sometime around May 19, 2027.

While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a maintained with a price target of $12.00 to $10.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $3.88, which is out of the analyst’s predicted range.